Performance in the US refractive surgery market was mixed in Q2-2012, with some surgeons reporting declines in volume while others saw healthy growth.
US IOL procedures remained roughly on pace with long-term trends, according to cataract surgeons responding to our recent survey.
FDA advisory committee voted unanimously that the benefits of administering ocriplasmin for symptomatic VMA outweigh risks.
The drug is the first to gain the FDA’s approval for this complication of diabetes.
As many as 6,000 doctors are expected in Italy for the ESCRS meeting, which some consider the most important gathering of the year.
The drug fails to win the backing of the agency that oversees health care costs in the UK.
Market Scope expects the global ophthalmic single-use surgical product market to generate $2.3 billion in sales in 2012.
You are not currently logged in.
©2017 Market Scope
Lost your Password